PTC Therapeutics (PTCT) said Wednesday that a new drug application for vatiquinone for the treatment of adults and children with Friedrich's ataxia has been accepted by the U.S. Food and Drug Administration for priority review.
The agency has set Aug. 19 as the target action date for the drug under the Prescription Drug User Fee Act.
Data from three studies showed that vatiquinone demonstrated "significant" evidence of slowing disease progression with regard to key aspects of the neuromuscular disease, the company said.
Shares were 3.3% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。